GLS's logo.
Ticker Symbol: GLS

Gelesis Holdings Inc

Exchange: NEW YORK STOCK EXCHANGE INC. Country: US Currency: USD Asset Type: Common Stock CIK:0001805087

Company Profile

Gelesis is a consumer-centered biotherapeutics company advancing a novel category of treatments for weight management and gut related chronic diseases. Its non-systemic superabsorbent hydrogels are the first and only made entirely from naturally derived building blocks, and they are inspired by the composition (i.e., water & cellulose) and mechanical properties (e.g., elasticity or firmness) of raw vegetables. They are conveniently administered in capsules to create a much larger volume of small, non-aggregating hydrogel pieces that become an integrated part of the meals, and act locally in the digestive system. Its portfolio includes Plenity®, an FDA-cleared product to aid in weight management, as well as potential therapies in development for patients with Type 2 Diabetes, Non-alcoholic Fatty Liver Disease (NAFLD)/Non-alcoholic Steatohepatitis (NASH), and Functional Constipation.

Sector: Professional, Scientific, and Technical Services
Industry: Research and Development in Biotechnology
Standard Industrial Classification Code (SIC code): 2834
Address: 501 Boylston Street
CEO: Yishai Zohar
Tags: N/A

Pricing

Last Updated: December 31, 1969 07:00 PM EST
Previous Close: -
Change: - ( 0.00%)
Days Range: $0.14 - $0.16
Beta: 1.47
52wk. High: $5.67
52wk. Low: $0.11
Ytd. Change -45.39%
50 Day Moving Average: $0.21
200 Day Moving Average: $0.40
Shares Outstanding: 73332588

Valuation

Market Cap: 1.2B
PE Ratio: -
EPS (TTM): 0

Dividends

Dividend Per Share (TTM): -
Dividend Yield (TTM): 0.00%
Ex-Dividend Date: N/A